CRMI China Regenerative Medicine International L : enters into a Strategic Framework Cooperation Agreement with Shanghai Lingang Songjiang High-tech Industrial Development Co., Ltd

[Press Release]

China Regenerative Medicine International Limited

(Stock Code: 8158.HK)

CRMI enters into a Strategic Framework Cooperation Agreement with Shanghai

Lingang Songjiang High-tech Industrial Development Co., Ltd

(16 January, 2018 - Hong Kong) - China Regenerative Medicine International Limited

("CRMI" or the "Company," stock code: 8158.HK, collectively the "Group") is pleased

to announce that CRMI entered into a strategic cooperation agreement framework with Shanghai Lingang Songjiang High-tech Industrial Development Co., Ltd("Shanghai Lingang Songjiang") ( 上海臨港松江高新產業發展有限公司 ). Mr.Dai Yumin,

Chairman of Medical Commission of CRMI and Mr.Shenming, the Mayor of Peoples'

Government on Jiuting town, Songjiang district, Shanghai, attended the signing ceremony and the agreement signed under their witness. Mr. Chen Chunguo, Chief

Executive Officer of CRMI and Mr. Liu Dehong, General Manager of Shanghai Lingang Songjiang High-tech Park Investment and Development Co., Ltd（上海臨港松江科技 城投資發展有限公司）on behalf of two parties signed a strategic cooperation agreement respectively.

Mr.Chen Chunguo, CEO of CRMI and Mr. Liu Dehong, General Manager of Shanghai Lingang SongjiangHigh-tech Park Investment and Development Co., Ltd on behalf of the two parties signed a strategic cooperation agreement respectively.

Shanghai Lingang Songjiang High-tech Industrial Development Co., Ltd(上海臨港松江 高新產業發展有限公司) belongs to Lingang Songjiang Tech city, and is involved in first pilot project on "Inter-regional Cooperation and Branding Connection" recognized by Shanghai municipal government, focusing on development and construction, operation, area service and investment and financing management of the industrial park.

CRMI, as China's first high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products, focuses on three major business segments namely tissue engineering, cell therapy, and cosmetics, its business spreads in Hong Kong, PRC and overseas.

The Science Oasis of Jiuting& Lingang Songjiang High-tech Park (the "Science Oasis") (九科綠洲臨港松江科技城) is situated in an ideal position on the "G60 Technology Corridor",a shining pearl in a gold belt on outer ring industry. Pursuant to the terms of the Agreement, Shanghai Lingang Songjiang High-tech Industrial Development Co., Ltd（上海臨港松江高新產業發展有限公司）will be a leading the development and construction of the Science Oasis site. CRMI is planning to set up the Group's PRC headquarters at the Science Oasis with three segments comprising an operation headquarters, an international engineering institute, and a high-end manufacturing area. Both parties will work together under the cooperative spirit of "complementary advantages, resource sharing and develop together", to progress the Company's establishment at the Science Oasis, and to make their own contributions to the local economic development.

The representatives of Shanghai Lingang Songjiang High-tech Park Investment and Development Co., Ltd（上海臨港松江科技城投資發展有限公司）and the representatives of peoples' government on Jiuting town, Songjiang district, Shanghai, as well as the department heads of CRMI attended the signing ceremony.

- END -

About China Regenerative Medicine International Limited

China Regenerative Medicine International Limited, listed on the GEM Board of The Stock Exchange (stock code: 8158) since 2001, is China's first high-end new-technology enterprise principally engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The Group has built up four major business segments, namely tissue engineering, cell therapy, cosmetics and hospital management. It has launched several iconic products including 'ActivSkin', the only tissue-engineered skin developed in China and 'Acornea', the world's first bio- engineered cornea which completed its clinical trials. The Company has applied for more than 140 domestic and overseas patents. Leveraging on its "CRMI Technology Centre at the University of Oxford", the Company is now engaged in construction of a whole industry chain of cell therapy. For more details, please visitwww.crmi.hk